Pfizer: Time And Patience Ran Out (Rating Downgrade)

Summary:

• Pfizer stock has outperformed healthcare peers recently, but investors shouldn’t assume that a sustained turnaround is close.
• Management attempted to assure investors about its operational growth in 2025 with a recent guidance update.
• However, Pfizer’s oncology promises are several years from being actualized. Competition in weight loss drugs has also grown.
• PFE could continue to suffer from being cheap, but not attractive enough, as its growth profile looks unappealing.
• I argue why the recent hammering across healthcare stocks has likely made PFE less attractive. Therefore, it’s time for PFE investors to consider moving on.

Pfizer (NYSE:PFE) (NEOE:PFE:CA) investors have outperformed their healthcare sector peers (XLV) over the past four to five weeks, even as investors digested possible structural headwinds attributed to the incoming Trump administration. Hence, it’s possible that the market has

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Important note: Investors are reminded to do their due diligence and not rely on the information provided as financial advice. Consider this article as supplementing your required research. Please always apply independent thinking. Note that the rating is not intended to time a specific entry/exit at the point of writing, unless otherwise specified.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

A Unique Price Action-based Growth Investing Service

• We believe price action is a leading indicator. 
• We called the TSLA top in late 2021.
• We then picked TSLA’s bottom in December 2022.
• We updated members that the NASDAQ had long-term bearish price action signals in November 2021.
• We told members that the S&P 500 likely bottomed in October 2022.
• Members navigated the turning points of the market confidently in our service.
• Members tuned out the noise in the financial media and focused on what really matters: Price Action.

Sign up now for a Risk-Free 14-Day free trial!